Michael C Hageman

US Patent:

6429195, Aug 6, 2002

Filed:

Sep 1, 2000

Appl. No.:

09/654156

Inventors:

Todd P. Foster - Kalamazoo MI
William M. Moseley - Augusta MI
James F. Caputo - Portage MI
Michael J. Hageman - Kalamazoo MI

Assignee:

Pharmacia Upjohn Company - Kalamazoo MI

International Classification:

A61K 3800

US Classification:

514 12, 514 2, 514805, 530399

Abstract:

Prolonged parenteral release into the circulatory system of a cow of a bioactive growth hormone releasing factor at desirably effective levels can be achieved using novel compositions in which the growth hormone releasing factor is present in an aqueous liquid at a dose of at least about 50 mg and at a concentration of at least about 20 mg/ml. Preferably, the growth hormone releasing factor is present in an aqueous liquid at a dose of about 200 mg and at a concentration of about 180 mg/ml. The aqueous bovine growth hormone releasing factor formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than seven (7) days.

US Patent:

6471977, Oct 29, 2002

Filed:

Aug 2, 1996

Appl. No.:

08/696985

Inventors:

Michael John Hageman - Kalamazoo MI 49009
Margaret Luise Possert - Kalamazoo MI 49009

International Classification:

A61K 3827

US Classification:

424422, 424426, 424438, 514 12, 514 21, 530399

Abstract:

Prolonged parenteral release into the circulatory system of a cow of a bioactive bovine somatotropin at desirably effective levels can be achieved using novel compositions in which the bovine somatotropin is present it an aqueous liquid at a dose of at least about 150 mg and at a concentration of at least about 50 mg/ml. The aqueous bovine somatotropin formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than three (3) days.

US Patent:

6699490, Mar 2, 2004

Filed:

Sep 16, 2002

Appl. No.:

10/244726

Inventors:

Michael John Hageman - Kalamazoo MI
Margaret Luise Possert - Kalamazoo MI

Assignee:

The Upjohn Co. - Kalamazoo MI

International Classification:

A61K 3827

US Classification:

424422, 424426, 424438, 514 12, 514 21, 530399

Abstract:

Prolonged parenteral release into the circulatory system of a cow of a bioactive bovine somatotropin at desirably effective levels can be achieved using novel compositions in which the bovine somatotropin is present in an aqueous liquid at a dose of at least about 150 mg and at a concentration of at least about 50 mg/ml. The aqueous bovine somatotropin formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than three (3) days.

US Patent:

6964978, Nov 15, 2005

Filed:

Dec 6, 2000

Appl. No.:

09/730663

Inventors:

Michael J. Hageman - Portage MI, US
Xiaorong He - Kalamazoo MI, US
Tugrul T. Kararli - Skokie IL, US
Lesley A. Mackin - Evanston IL, US
Patricia J. Miyake - Tower Lakes IL, US
Brian R. Rohrs - Scotts MI, US
Kevin J. Stefanski - Kalamazoo MI, US

Assignee:

Pharmacia Corporation - St. Louis MO

International Classification:

A61K031/415
C07D231/10

US Classification:

514406, 5483561, 5483731, 5483751, 5483761

Abstract:

The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.

US Patent:

7172769, Feb 6, 2007

Filed:

Dec 6, 2000

Appl. No.:

10/031898

Inventors:

Tugrul T. Kararli - Skokie IL, US
Mark J. Kontny - Libertyville IL, US
Subhash Desai - Wilmette IL, US
Michael J. Hageman - Portage MI, US
Royal J. Haskell - Kalamazoo MI, US

Assignee:

Pharmacia Corporation - St. Louis MO

International Classification:

A61K 9/50

US Classification:

424501, 424489

Abstract:

Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particle, about 25% to 100% by weight of which are smaller than 1 μm. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.

US Patent:

7220867, May 22, 2007

Filed:

Jul 26, 2005

Appl. No.:

11/189659

Inventors:

Michael J. Hageman - Portage MI, US
Xiaorong He - Kalamazoo MI, US
Tugrul T. Kararli - Skokie IL, US
Lesley A. MacKin - Evanston IL, US
Patricia J. Miyake - Tower Lakes IL, US
Brian R. Rohrs - Scotts MI, US
Kevin J. Stefanski - Kalamazoo MI, US

Assignee:

Pharmacia Corporation (of Pfizer, Inc.) - St. Louis MO

International Classification:

C07D 231/10

US Classification:

5483751, 5483561, 5483731, 5483761

Abstract:

The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.

US Patent:

20020142045, Oct 3, 2002

Filed:

Apr 1, 2002

Appl. No.:

10/113157

Inventors:

Tugrul Kararli - Skokie IL, US
Mark Kontny - Libertyville IL, US
Subhash Desai - Wilmette IL, US
Michael Hageman - Portage MI, US
Royal Haskell - Kalamazoo MI, US
Fred Hassan - Peapack NJ, US
James Forbes - Glenview IL, US

International Classification:

A61K031/522
A61K009/14

US Classification:

424/489000, 514/263310, 514/263320

Abstract:

Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particles, about 25% to 100% by weight of which are smaller than 1 m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.

US Patent:

20030045563, Mar 6, 2003

Filed:

Jan 15, 2002

Appl. No.:

10/047222

Inventors:

Ping Gao - Portage MI, US
Michael Hageman - Portage MI, US
Walter Morozowich - Kalamazoo MI, US
Robert Dalga - Kalamazoo MI, US
Kevin Stefanski - Kalamazoo MI, US
Tiehua Huang - Kalamazoo MI, US
Aziz Karim - Skokie IL, US
Fred Hassan - Peapack NJ, US
James Forbes - Glenview IL, US

International Classification:

A61K031/415
A61K031/44
A61K031/4439
A61K031/18
A61K031/10

US Classification:

514/406000, 514/341000, 514/602000, 514/709000

Abstract:

An orally deliverable pharmaceutical composition is provided comprising a drug of low water solubility, a solvent liquid that comprises at least one pharmaceutically acceptable solvent, and a turbidity-decreasing polymer, wherein (a) a substantial portion, for example at least about 15% by weight, of the drug is in dissolved or solubilized form in the solvent liquid, and (b) the polymer is present in an amount sufficient to substantially inhibit crystallization and/or precipitation of the drug in simulated gastric fluid.